Biosketch / Results /

Douglas Dieterich

Adjunct Professor, Department of Medicine

Contact Info

212-241-4299
Douglas.Dieterich@nyumc.org

Education

1978-1979 — NYU Medical Center, Internship
1979-1981 — NYU Medical Center (Medicine), Residency Training
1979-1981 — NYU Medical Center, Residency Training
1981-1983 — NYU Medical Center (Gastroenterology), Clinical Fellowships

Research Summary

Spector, S., Weingeist, T., Pollard, R.B., et al. A randomized controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J. Infect. Dis. 1993; 168:557-560.

Dieterich D.T., Poles, M.A., Lew, E.A., et al. Concurrentl use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J. Infect. Dis. 1993; 167: 1184-1188.

Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. 4. Visual Outcomes. Ophthalmology. 1994; 101: 1250-1261.

Studies of Ocular complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial-3. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch. Int. Med. 1995;155: 65-74.

Studies of Ocular complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Foscarnet-GanciclovirCytomegalovirus Retinitis Trial-4. Visual outcomes. Ophthalmology.1994; 101: 1250-1261.

Department of Medicine Faculty Listing


Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study
Tapper, E B; Bacon, B R; Curry, M P; Dieterich, D T; Flamm, S L; Guest, L E; Kowdley, K V; Lee, Y; Tsai, N C; Younossi, Z M; Afdhal, N H. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. Journal of viral hepatitis. 2017 Jan;24(1):22-27 (2382282)

Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study
Tapper, Elliot B; Bacon, Bruce R; Curry, Michael P; Dieterich, Douglas T; Flamm, Steven L; Guest, Lauren E; Kowdley, Kris V; Lee, Yoori; Tsai, Naoky C; Younossi, Zobair M; Afdhal, Nezam H. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016 Dec;64(6):1893-1899 (2310142)

Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care
Younossi, Zobair M; Park, Haesuk; Dieterich, Douglas; Saab, Sammy; Ahmed, Aijaz; Gordon, Stuart C. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore). 2016 Oct;95(41):e5048-e5048 e5048 (2279132)

Effect of ethnicity on HCV patient outcomes and access to therapy in era of all DAA regimens: Real-world experience from the trio network
Korenblat, K M; Bacon, B; Curry, M P; Dieterich, D T; Flamm, S L; Guest, L; Kowdley, K V; Lee, Y; Tsai, N C S C; Younossi, Z M; Afdhal, N H. Effect of ethnicity on HCV patient outcomes and access to therapy in era of all DAA regimens: Real-world experience from the trio network [Meeting Abstract]. Hepatology. 2016 Oct;Conference:(67th):1006A-1007A (2311272)

A Decision analytic markov model to evaluate the health outcomes of sofosbuvir/velpatasvir for patients with chronic hepatitis C virus genotype 2 and 3 infection in the US
Gordon, S C; Ahmed, A; Kugelmas, M; Dieterich, D T; Wong, R; Brown, K A; Saab, S; Younossi, Z M. A Decision analytic markov model to evaluate the health outcomes of sofosbuvir/velpatasvir for patients with chronic hepatitis C virus genotype 2 and 3 infection in the US [Meeting Abstract]. Hepatology. 2016 Oct;Conference:(67th):422A-423A (2311282)